Core Viewpoint - Tongce Medical (600763) experienced a slight decline in stock price, closing at 43.31 yuan on November 3, 2025, with a trading volume of 42,500 hands and a total transaction amount of 184 million yuan [1] Group 1: Financial Performance - For the first three quarters of 2025, Tongce Medical reported a main business revenue of 2.29 billion yuan, a year-on-year increase of 2.56% [3] - The net profit attributable to shareholders for the same period was 514 million yuan, up 3.16% year-on-year [3] - The third quarter of 2025 saw a single-quarter main business revenue of 842 million yuan, reflecting a year-on-year increase of 2.34% [3] - The company’s gross profit margin stood at 41.69%, significantly higher than the industry average of 35.56% [3] Group 2: Market Position and Valuation - Tongce Medical's total market capitalization is 19.372 billion yuan, ranking 8th in the medical services industry [3] - The company has a price-to-earnings ratio (P/E) of 28.29, which is considerably lower than the industry average of 382.07, ranking 3rd in the industry [3] - The return on equity (ROE) for Tongce Medical is 11.8%, significantly higher than the industry average of 3.24%, ranking 5th in the industry [3] Group 3: Fund Flow Analysis - On November 3, 2025, the net outflow of main funds was 1.6885 million yuan, accounting for 0.92% of the total transaction amount [2] - Over the past five days, the stock has seen fluctuations in fund flows, with notable net inflows and outflows from different investor categories [2] - The average target price set by institutions over the past 90 days is 52.01 yuan, with 7 buy ratings and 2 hold ratings [4]

Core Viewpoint - The article highlights the phenomenon of "zombie stocks" in the A-share market, where companies with declining stock prices continue to report profits, leading to perplexing situations for investors [1][3][5]. Group 1: Stock Performance - A stock that was listed in April 2015 at a price of 5.47 yuan peaked at 72 yuan but has since fallen to 3.67 yuan, representing a 93.5% decline over ten years [1]. - Another company, Shanying International, saw its stock price drop from a high of 62.64 yuan to 1.62 yuan, a decline of 97.4%, while facing a 13% year-on-year drop in corrugated paper prices in 2024 [3]. - Watson Bio's stock price fell from 12.20 yuan in May 2015 to a cumulative decline of 18%, with a peak drop of 89.6% from its historical high of 96.73 yuan [3]. - Tongce Medical's stock price plummeted from 300.98 yuan to 40.13 yuan, an 88% decline, despite a market peak where its P/E ratio exceeded 200 [3]. - Chongqing Steel has reported losses for three consecutive years, with a projected loss of 1.26 billion yuan in 2024, amid an oversupply in the steel industry [3]. Group 2: Company Fundamentals - BWS, a veteran in the water treatment industry, has annual revenues exceeding 9 billion yuan but has seen its stock price decline for five consecutive years due to liquidity issues, with a daily trading volume below 100 million yuan [5]. - Huaping Co. has raised 980 million yuan since its listing but has only distributed 31 million yuan in dividends, with major shareholders cashing out 230 million yuan [5]. - Dongjiang Environmental, another established player in environmental management, has seen its stock price drop from 30.30 yuan to 4.54 yuan, an 85% decline, with continuous losses reported [7]. Group 3: Market Trends and Investor Behavior - The A-share market contains numerous stocks that have been in a downward trend for ten years, characterized by persistent declines and failed bottom-fishing attempts by investors [5][9]. - Extreme cases include companies like Baofeng Group, which fell from 327.01 yuan to a delisting price of 0.28 yuan, a 99.9% drop, and LeTV, which dropped from 179.03 yuan to 0.31 yuan, a 99% decline [5]. - Investors often make the mistake of blindly bottom-fishing and trusting low-priced stocks, leading to deeper losses as seen with BWS shareholders who increased their holdings during price declines [7][9]. Group 4: Identifying Zombie Stocks - Zombie stocks typically exhibit characteristics such as a long-term average turnover rate below 1%, minimal price fluctuations, continuous performance declines, and lack of institutional coverage [9]. - Fundamental screening is crucial to avoid risks, with recommendations to steer clear of companies with declining revenues or high debt ratios, while favoring financially healthy industry leaders [9]. - Data indicates that stocks with declines exceeding 90% rarely return to historical highs, often remaining stagnant or heading towards delisting [9].

Core Viewpoint - Tongce Medical (600763) shows a positive performance with a closing price of 43.45 yuan, up 1.8% as of October 31, 2025, indicating a stable market interest in the company [1]. Financial Performance - For the first three quarters of 2025, Tongce Medical reported a main revenue of 2.29 billion yuan, a year-on-year increase of 2.56% [3]. - The net profit attributable to shareholders reached 514 million yuan, up 3.16% year-on-year, while the net profit after deducting non-recurring gains and losses was 509 million yuan, increasing by 3.09% [3]. - In Q3 2025, the company achieved a single-quarter main revenue of 842 million yuan, a year-on-year increase of 2.34%, and a net profit of 192 million yuan, up 2.31% [3]. Market Activity - On October 31, 2025, the net inflow of main funds was 14.46 million yuan, accounting for 4.78% of the total transaction amount, while retail investors experienced a net outflow of 3.39 million yuan, representing 1.12% of the total [1][2]. - Over the past five days, the stock has seen fluctuations in fund flows, with varying levels of net inflow and outflow from different investor categories [2]. Industry Comparison - Tongce Medical's total market capitalization stands at 19.435 billion yuan, ranking 8th in the medical services industry, while its net profit ranks 6th [3]. - The company has a price-to-earnings ratio of 28.39, significantly lower than the industry average of 375.95, indicating a potentially undervalued position [3]. Analyst Ratings - In the last 90 days, 9 institutions have rated the stock, with 7 buy ratings and 2 hold ratings, suggesting a generally positive outlook among analysts [4]. - The average target price set by institutions is 52.01 yuan, indicating potential upside from the current trading price [4].

Core Viewpoint - Tongce Medical (600763) shows a stable performance with a slight increase in stock price and mixed capital flow, indicating potential investor interest despite some outflows from institutional and speculative funds [1][2]. Group 1: Stock Performance - As of October 29, 2025, Tongce Medical's stock closed at 42.99 yuan, up by 0.99% with a turnover rate of 1.27% and a trading volume of 56,600 hands, resulting in a transaction amount of 242 million yuan [1]. - Over the past five days, the stock has experienced fluctuations in capital flow, with a net outflow of 662.74 million yuan on October 29, 2025, while retail investors saw a net inflow of 757.1 million yuan [2]. Group 2: Financial Metrics - For the first three quarters of 2025, Tongce Medical reported a main revenue of 2.29 billion yuan, a year-on-year increase of 2.56%, and a net profit attributable to shareholders of 514 million yuan, up by 3.16% [3]. - The company's third-quarter performance included a single-quarter main revenue of 842 million yuan, reflecting a 2.34% year-on-year increase, and a net profit of 192 million yuan, up by 2.31% [3]. - Key financial ratios include a total market value of 19.229 billion yuan, a net asset of 4.703 billion yuan, and a net profit margin of 26.91%, which is significantly higher than the industry average [3]. Group 3: Institutional Ratings - In the last 90 days, nine institutions have rated Tongce Medical, with seven giving a "buy" rating and two an "increase" rating, indicating positive sentiment among analysts [4]. - The average target price set by institutions over the past 90 days is 52.01 yuan, suggesting potential upside from the current trading price [4].

Summary of Tongce Medical Conference Call Company Overview - **Company**: Tongce Medical - **Industry**: Dental Care and Orthodontics Key Financial Performance - **Revenue Growth**: In the first three quarters of 2025, revenue reached 22.9 billion CNY, a year-on-year increase of 2.56% [3] - **Net Profit**: Net profit attributable to shareholders was 5.16 billion CNY, up 3.16% year-on-year [2] - **Cash Flow**: Operating cash flow increased by 5.34% to 6.82 billion CNY [2] - **Earnings Per Share**: Basic earnings per share were 1.15 CNY, a 3.6% increase [3] Operational Highlights - **Zijin Port Hospital**: Achieved an average monthly output of approximately 4 million CNY since opening, contributing to profitability [2][6] - **Orthodontics Revenue**: Increased by 7.8% to 4.26 billion CNY in the first three quarters, with a third-quarter revenue of 1.97 billion CNY [8][16] - **Implant Sales**: Number of implants remained stable at around 40,000 units, with a unit price of 8,000 CNY [10] Strategic Initiatives - **Reform and Integration**: The company is undergoing comprehensive reforms to vertically integrate departments and optimize doctor-client matching to enhance productivity [2][11] - **Expansion Plans**: Plans to resume steady growth from 2026 and prepare for future external franchise opportunities [11][12] - **Franchise Strategy**: Franchise plans are on hold until the intelligent system is fully developed to ensure effective resource organization [12] Market Dynamics - **Industry Trends**: The orthodontics collective procurement is progressing well, with some regions seeing price increases, which is favorable for the industry [4][13] - **Competition**: The industry is experiencing a balance between new openings and closures, with an increase in small clinics and a decrease in large institutions [15] Future Outlook - **2026 Projections**: The company aims to significantly increase productivity and market share, particularly in Zhejiang province, with a focus on optimizing internal resources [11][23] - **AI Integration**: Plans to leverage AI technology for operational efficiency and resource allocation [20] - **Dividend Expectations**: The company intends to increase dividend payouts as capital expenditures decrease [18] Additional Insights - **Doctor Management**: A new assessment system will be implemented in 2026 to improve doctor efficiency and align incentives with performance [19] - **Market Share Challenges**: The company faces challenges in maintaining market share against public hospitals, particularly in lower-tier markets [21] - **Demand Stability**: No signs of deferred demand for implants due to upcoming collective procurement renewals [22] This summary encapsulates the key points from the conference call, highlighting the financial performance, operational strategies, market dynamics, and future outlook of Tongce Medical.

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected price increase of over 15% in the next 6-12 months [5][11]. Core Insights - The company achieved a revenue of 2.29 billion RMB in the first three quarters of 2025, reflecting a year-on-year growth of 2.56%. The net profit attributable to shareholders was 514 million RMB, up 3.06% year-on-year [2]. - The company's gross margin for the first three quarters was 41.69%, showing a slight decrease of 0.13 percentage points year-on-year, while the net profit margin was 26.91%, down 0.04 percentage points year-on-year [3]. - The company has successfully launched the largest general hospital in the Hangzhou area, which is expected to enhance its brand influence and operational capacity [4]. Financial Performance - For Q3 2025, the company reported a revenue of 842 million RMB, a year-on-year increase of 2.34%, and a net profit of 192 million RMB, up 2.06% year-on-year [2]. - The operating cash flow for the first three quarters was 682 million RMB, representing a growth of 5.39% year-on-year, indicating strong cash collection capabilities [3]. - The company forecasts net profits of 526 million RMB, 556 million RMB, and 591 million RMB for 2025, 2026, and 2027 respectively, with expected growth rates of 5%, 6%, and 6% [5]. Operational Analysis - The company has maintained a stable cost control and operational efficiency despite industry changes, particularly in the dental implant sector [3]. - The company is expanding its hospital network, with expectations to reach over 90 medical institutions by the end of the year, which will support future growth [4].

Core Viewpoint - Tongce Medical's performance shows signs of weakness, with revenue and net profit growth rates below 5%, indicating a lack of robust growth [2][6]. Financial Performance - In the first three quarters of 2025, Tongce Medical achieved revenue of 2.29 billion yuan, a year-on-year increase of 2.56%, and a net profit attributable to shareholders of 514 million yuan, up 3.16% year-on-year [1]. - The company's net profit has shown a decline over the past three years, with figures of 515 million yuan, 512 million yuan, and 498 million yuan for the respective periods from 2022 to 2024, reflecting year-on-year decreases of 16.92%, 0.67%, and 2.63% [2]. Historical Context - Tongce Medical, known as "Tooth Ma," has experienced significant growth since its reverse merger in 2007, with revenue and net profit increasing from 91 million yuan and 10 million yuan, respectively [2]. - The company saw a return to high growth in 2021 after a pandemic-related downturn in 2020, with net profit growth rates exceeding 50% [2]. Mergers and Acquisitions - In recent years, Tongce Medical has actively pursued acquisitions, including stakes in multiple dental and medical companies, such as a 50% stake in Hangzhou Qingchun Dental Clinic and a 38.75% stake in Shanghai Sanyue Children's Dental Hospital [3][4]. - The company announced a total transaction amount of 55.41 million yuan for the acquisition of 100% equity and debt of Hangzhou Haiyin Technology Co., Ltd. from its controlling shareholder [4]. Challenges and Market Factors - Despite the acquisitions, they have not yet positively impacted Tongce Medical's operating performance [5]. - The company faces market challenges, including price competition from peers, which has contributed to its sluggish growth [6]. - Research and development investment has stagnated, with figures remaining relatively flat over the past few years, and the gross profit margin has been declining, from 47.96% in 2021 to 41.69% in 2025 [6].

Group 1: Macroeconomic Insights - In September, industrial enterprises' profits improved year-on-year to 21.6%, up from 20.4% in August, driven by a low base effect and strong export performance [3] - Revenue growth for industrial enterprises also increased to 3.1% in September from 2.3% in August, indicating a positive trend in cash flow due to anti-involution policies [3] Group 2: Fixed Income Market Analysis - The bond market has shown signs of recovery in October, influenced by trade tensions and a loose liquidity environment, with expectations for a better fourth quarter compared to the third [5] - The market anticipates a controlled impact from new redemption regulations, with a focus on short to medium-term credit bonds as a primary investment strategy [5] Group 3: Oil and Gas Sector - Oil prices have entered a downward trend due to OPEC+ increasing production targets and seasonal demand decline, with Brent crude expected to average $68 in 2025 and $62 in 2026 [9] - Despite short-term volatility from geopolitical tensions, the long-term outlook suggests limited impact from sanctions on oil prices, with high-dividend energy companies presenting investment opportunities [9] Group 4: Real Estate and Construction - The real estate market is experiencing a decline in transaction volumes for both new and second-hand homes, attributed to high base effects and seasonal factors [8] - The construction sector shows mixed signals, with some recovery in cement supply and demand, while asphalt production rates have decreased [8] Group 5: Key Company Performances - Beike-W (2423 HK) is projected to benefit from a gradual market recovery, with a target price of HKD 65.64 based on a 26x PE ratio for 2026 [11] - Zhiou Technology (301376 CH) reported a revenue of CNY 60.8 billion for the first three quarters, with a year-on-year growth of 6.2%, and is expected to improve profitability as tariff risks ease [12] - Tianhai Defense (300008 CH) showed significant growth in Q3, with a revenue increase of 57.27% year-on-year, driven by strong orders in shipbuilding and defense sectors [14] - Kuka Home (603816 CH) reported steady revenue growth of 6.5% in Q3, with a focus on global expansion and brand strength [15] - Weixing New Materials (002372 CH) experienced a revenue decline of 9.83% in Q3, but is expected to see margin recovery as product prices stabilize [16] Group 6: Consumer Goods and Services - Salted Fish (002847 CH) reported a revenue increase of 14.7% year-on-year, with a focus on optimizing product categories and channels to enhance profitability [27] - Petty Co. (300673 CH) continues to see strong growth in its domestic brand, with a focus on single product strategies despite challenges in overseas markets [18] - Jiangsu Bank (601009 CH) reported a steady growth in net profit and revenue, driven by stable interest income and effective cost management [32]

Core Insights - The best-performing fund managed by fund manager Luo Shifeng is the Nord Cycle Strategy Mixed Fund (570008), which achieved a quarterly net value increase of 52.47% by the end of Q3 2025 [1] Fund Performance Summary - The Nord Value Advantage Mixed Fund (570001) has a total fund size of 24.81 billion, with an annualized return of 7.58% and a Q3 2025 increase of 44.93%, with its top holding being Sungrow Power [2] - The Nord Cycle Strategy Mixed Fund (570008) has a fund size of 9.26 billion, an annualized return of 15.18%, and a Q3 2025 increase of 52.47%, with its top holding being NewEase [2] - The Nord Value Discovery - Annual Holding Mixed Fund (012150) has a fund size of 5.39 billion, with a negative annualized return of -0.97% and a Q3 2025 increase of 26.73%, with its top holding also being Sungrow Power [2] Stock Trading Cases - Notable stock trading cases managed by Luo Shifeng include: - Sungrow Power: Bought in Q3 2020 and sold in Q1 2021, with an estimated return of 300.71% and a company performance growth of 25.15% during the holding period [3] - Longi Green Energy: Held from Q1 2018 to Q2 2023, with an estimated return of 231.97% and a company performance growth of 488.96% [3] - Midea Group: Held from Q2 2016 to Q4 2017, with an estimated return of 136.18% and a company performance growth of 51.35% [3] Underperforming Stock Cases - Underperforming stock cases include: - Opcon Vision: Bought in Q3 2021 and sold in Q1 2024, with an estimated return of -76.32% despite a company performance growth of 40.04% [4] - Tongce Medical: Held from Q3 2021 to Q2 2023, with an estimated return of -63.37% and a company performance growth of 2.37% [4] - Sanan Optoelectronics: Held from Q4 2017 to Q2 2019, with an estimated return of -51.40% [4]

Core Points - The company guarantees the authenticity, accuracy, and completeness of the quarterly report, and assumes legal responsibility for any false records or significant omissions [2][3]. Financial Data - The third-quarter financial statements are not audited [3]. - The company completed the acquisition of 100% equity of Hangzhou Haiyin Technology Co., Ltd. in October 2024, and the acquisition of 100% equity of Shanghai Cunjie Hospital Dental Clinic Co., Ltd. in August 2025, which required retrospective adjustments according to accounting standards [4]. - The net profit of the acquired entities before the merger was -269,479.05 yuan, compared to -495,829.58 yuan in the previous period [8]. Non-Recurring Gains and Losses - The company has identified significant non-recurring gains and losses not listed in the relevant announcement, and will provide explanations for any reclassification of items [5]. Shareholder Information - There are no changes in the top ten shareholders or any significant changes in share lending activities during the reporting period [7].